Drugs / Autologous CD133+ stem cells
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01467232 Comparator | Sep 2011 → Nov 2014 | heart failure, myocardial infarction | University Health Network, Toronto | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD133+ stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01467232 ↗ |
| Action | Restore | “proved to be valuable for cardiac repair by promoting neovascularization, inhibition of apoptosis and cardiomyogenesis” NCT01467232 ↗ |
| Modality | Cell therapy | “cellular therapy is a potential approach to repopulate the injured myocardium” NCT01467232 ↗ |